VALNEVA (EPA:VLA) | Finanzwire

Basculer en Français

8302	Companies
115125	Keywords
55448	Articles
62531	Press releases

Home
Companies
VALNEVA

PRESS RELEASE

published on 08/20/2024 at 16:01, 3 months 1 day ago

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH updates research on Valneva SE (ISIN: FR0004056851) with a BUY recommendation and EUR 8.60 price target. H1 product sales slightly below consensus but gross margin improving. Valneva maintains full-year guidance

First Berlin Equity Research Buy Recommendation Valneva SE EUR 8.60 Price Target H1 Product Sales
BRIEF

published on 08/13/2024 at 07:05, 3 months 8 days ago

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

Financial Results Cash Position Revenue Guidance Valneva Vaccine Development
PRESS RELEASE

published on 08/13/2024 at 07:00, 3 months 8 days ago

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates
Valneva reports first-half 2024 financial results as total revenues reach €70.8 million with net profit of €34.0 million. Company confirms full-year guidance and updates strategic pipeline expansion

Revenues Financial Results Net Profit Valneva Strategic Pipeline
BRIEF

published on 08/06/2024 at 08:35, 3 months 15 days ago

Valneva Announces Share and Voting Right Changes as of July 31, 2024

Euronext Paris Voting Rights Shares Biopharmaceutical Valneva
PRESS RELEASE

published on 08/06/2024 at 08:30, 3 months 15 days ago

VALNEVA - Declaration of shares and voting rights: July 31, 2024
VALNEVA declared changes in shares and voting rights including sale, transfer, and granting of double voting rights on various dates

Voting Rights Shares Sale Transfer Valneva
BRIEF

published on 07/17/2024 at 22:05, 4 months 4 days ago

VALOR Phase 3 Trial: Valneva and Pfizer Finalize Primary Lyme Disease Vaccination

Clinical Test Valneva Pfizer VLA15 Lyme
PRESS RELEASE

published on 07/17/2024 at 22:00, 4 months 4 days ago

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion
Phase 3 VALOR Lyme Disease Trial: Pfizer and Valneva announce completion of primary vaccination series with VLA15, progressing towards a Lyme disease vaccine

Valneva Lyme Disease Vaccine Pfizer VLA15 VALOR
BRIEF

published on 06/05/2024 at 07:05, 5 months 16 days ago

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Executive Changes Corporate Update Valneva Shareholder Meeting
PRESS RELEASE

published on 06/05/2024 at 07:00, 5 months 16 days ago

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
Valneva announces availability of documentation for its Combined Shareholder Meeting on June 26, 2024, along with corporate update including change in General Counsel & Corporate Secretary. Kendra Wergin appointed as successor

Corporate Update Valneva General Counsel Shareholder Meeting Kendra Wergin
BRIEF

published on 05/21/2024 at 07:05, 6 months ago

Valneva appoints Dr Hanneke Schuitemaker as Scientific Director

Nomination R&D Valneva Vaccines Dr Hanneke Schuitemaker

Accesswire

Published on 11/22/2024 at 00:00, 21 minutes ago

Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 2 hours 16 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 2 hours 31 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 4 hours 6 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 4 hours 11 minutes ago

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 19:01, 5 hours 19 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 5 hours 45 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 6 hours 22 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 6 hours 29 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 6 hours 29 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.

Les Echos

Published on 11/21/2024 at 06:58, 17 hours 23 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 5 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 6 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 6 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 16 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE